Cytokine conjugates
AssigneeAmunix Pharmaceuticals, Inc.
InventorsVolker SCHELLENBERGER, Eric JOHANSEN, Angela HENKENSIEFKEN, Bryan IRVING, Tracy YOUNG, Vibha CHAUHAN, Valentine YEUNG
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising biologically active proteins, such as cytokines, linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of related disorders and conditions.
Claims28
A fusion protein comprising:
- (a) an extended recombinant polypeptide characterized in that:
- i) it comprises at least 12 amino acid residues;
- ii) at least 90% of the amino acid residues of the extended recombinant polypeptide are selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P);
- and
- iii) it has 4-6 different amino acid residues selected from G, A, S, T, E and P;
- (b) a cytokine;
- and
- (c) a linker joining the cytokine and the extended recombinant polypeptide, wherein the linker comprises a release segment (RS).
5-7. (canceled)
10-11. (canceled)
16-17. (canceled)
(canceled)
23-27. (canceled)
29-30. (canceled)
32-34. (canceled)
A fusion protein comprising a disulfide-linked heterodimer,
- wherein the disulfide-linked heterodimer comprises a first subunit and a second subunit,
- wherein the first subunit comprises the following elements in a N-to-C terminal or a C-to-N terminal orientation:
- (a) an extended recombinant polypeptide characterized in that:
- i) it comprises at least 12 amino acid residues;
- ii) at least 90% of the amino acid residues of the extended recombinant polypeptide are selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P);
- and
- iii) it has 4-6 different amino acid residues selected from G, A, S, T, E and P;
- (b) a release segment (RS);
- and
- (c) a first cytokine fragment (Cy1);
- wherein the second subunit comprises the following elements in a N-to-C terminal or a C-to-N terminal orientation:
- (d) an extended recombinant polypeptide characterized in that:
- i) it comprises at least 12 amino acid residues;
- ii) at least 90% of the amino acid residues of the extended recombinant polypeptide are selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P);
- and
- iii) it has 4-6 different amino acid residues selected from G, A, S, T, E and P;
- (e) a release segment (RS);
- and
- (f) a second cytokine fragment (Cy2).
A kit comprising at least a first container, the first container comprising:
- (a) an amount of a fusion protein sufficient to treat a disease, condition, or disorder upon administration to a subject in need thereof,
- (b) an amount of a pharmaceutically acceptable carrier, together in a formulation ready for injection or for reconstitution with sterile water, buffer, or dextrose.
Dependencies are inferred from the claim text.